AbbVie Stock-Based Compensation 2010-2025 | ABBV

AbbVie stock-based compensation for the twelve months ending March 31, 2025 was $2.634B, a 19.24% increase year-over-year.

  • AbbVie annual stock-based compensation for 2024 was $0.911B, a 21.95% increase from 2023.
  • AbbVie annual stock-based compensation for 2023 was $0.747B, a 11.33% increase from 2022.
  • AbbVie annual stock-based compensation for 2022 was $0.671B, a 3.03% decline from 2021.

AbbVie Stock-Based Compensation 2010-2025 | ABBV

  • AbbVie annual stock-based compensation for 2024 was $0.911B, a 21.95% increase from 2023.
  • AbbVie annual stock-based compensation for 2023 was $0.747B, a 11.33% increase from 2022.
  • AbbVie annual stock-based compensation for 2022 was $0.671B, a 3.03% decline from 2021.
Related Stocks
Company NameMarket
Cap
Eli Lilly (LLY)$796.4B
Johnson & Johnson (JNJ)$379.5B
Novo Nordisk (NVO)$260.6B
Roche Holding AG (RHHBY)$248.1B
Novartis AG (NVS)$234.2B
Merck (MRK)$196.7B
Sanofi (SNY)$128.6B
Pfizer (PFE)$125.6B
Bayer (BAYRY)$23.7B
Innoviva (INVA)$1.1B